Overview
CELC market data
Price History
CELC price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.79 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.08 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $44.42 – $151.02 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $4.4B · P/B 45.90.
Company News
HC Wainwright & Co. Reiterates Buy on Celcuity, Maintains $155 Price TargetBenzinga · Aug 14, 2026, 5:24 PM
Celcuity shares are trading higher after the company reported better-than-expected Q2 adjusted EPS results.Benzinga · Aug 14, 2026, 3:12 PM
Celcuity Analysts Slash Their Forecasts After Q2 LossBenzinga · Aug 14, 2026, 12:29 PM
Stifel Maintains Buy on Celcuity, Lowers Price Target to $150Benzinga · Aug 14, 2026, 12:21 PM
Needham Maintains Buy on Celcuity, Lowers Price Target to $140Benzinga · Aug 14, 2026, 10:20 AM
Celcuity Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga · Aug 13, 2026, 9:24 PM
Celcuity Q2 Adj. EPS $(1.07) Beats $(1.17) EstimateBenzinga · Aug 13, 2026, 8:09 PM
Celcuity's REVTORPYK Receives Recommendation From National Comprehensive Cancer Network Clinical Practice Guidelines In Oncology As Preferred Category 1 Second-Line TherapyBenzinga · Jul 30, 2026, 12:33 PM
NASDAQ: CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the FirmGlobenewswire Inc · Jul 29, 2026, 3:15 PM
CELCUITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the FirmGlobenewswire Inc · Jul 21, 2026, 10:00 PM